Technology
Health
Biotechnology

Tiziana Life Sciences

$7.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.64 (-7.74%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell TLSA and other stocks, options, ETFs, and crypto commission-free!

About

Tiziana Life Sciences plc American Depository Share, also called Tiziana Life Sciences, is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. Read More The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.

Employees
10
Headquarters
London, Greater London
Founded
2013
Market Cap
Price-Earnings Ratio
Dividend Yield
Average Volume
2.76K
High Today
$8.47
Low Today
$8.22
Open Price
$8.47
Volume
215.00
52 Week High
$12.17
52 Week Low
$5.00

Collections

Technology
Health
Biotechnology
Research And Development
Pharmaceutical
2018 IPO
UK
Europe

News

Seeking AlphaApr 25

NASH player Tiziana up 40% after Gilead flop

Ultra-thinly traded micro cap Tiziana Life Sciences (TLSA +40.2% ) is up on almost a 10x surge in volume, albeit on turnover of only 17.4K shares, in apparent reaction to the failure of another late-stage study of Gilead Sciences' selonsertib.

384

Earnings

-$0.08
-$0.07
-$0.07
-$0.06
Q4 2018
Q1 2019
Estimated
-$0.07 per share
Actual
Expected May 28, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.